News

March 16, 2017

AveXis Reports Results from Phase 1 Trial of AVXS-101

AveXis Reports Results from Phase 1 Trial of AVXS-101

AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported

READ MORE   |  

Topics: Clinical Trials, Front Page News

March 15, 2017

Know Your Resources: How Congressional Caseworkers Can Help You Obtain Insurance Coverage for New Therapies

Know Your Resources: How Congressional Caseworkers Can Help You Obtain Insurance Coverage for New Therapies

Your elected officials who represent you in Washington, D.C. have caseworkers in their regional and district offices in your communities. These caseworkers can help you work with and better understand government programs, like Medicaid, Medicare, TRICARE, and Social...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

March 15, 2017

Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University

Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University

Cure SMA has awarded a $140,000 research grant to Arthur Burghes, PhD, at The Ohio State University, for his project, "Identification of SMA modifiers and deletion/duplication junctions in the SMA region.”

All individuals with SMA lack the SMN1 gene, but have one or more...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

Items 4 - 6 of 320  Previous12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software